Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma

Zhan, Weixiang; Bai, Fan; Cai, Yue; Zhang, Jianwei; Qin, Ge; Xie, Yuqian; Deng, Yanhong

doi:10.7150/jca.87618



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(16):2998-3008. doi:10.7150/jca.87618 This issue Cite

Research Paper

Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma

Weixiang Zhan^1,2,3*, Fan Bai^1,2,3*, Yue Cai^1,2,3*, Jianwei Zhang^1,2,3, Ge Qin^1,2,3, Yuqian Xie^1,2,3, Yanhong Deng^1,2,3✉

1. Department of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, Guangdong Research Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
3. Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
* These authors have contributed equally to this work.

Citation:

Zhan W, Bai F, Cai Y, Zhang J, Qin G, Xie Y, Deng Y. Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma. J Cancer 2023; 14(16):2998-3008. doi:10.7150/jca.87618. https://www.jcancer.org/v14p2998.htm

Other styles

Abstract

Sialic acid binding Ig-like lectin 15 (Siglec15) is considered a novel immune checkpoint and an emerging target for next-generation cancer immunotherapy. However, the significance of Siglec15 and its relationship with programmed death-ligand 1 (PD-L1) in colon adenocarcinoma (COAD) remain unknown. In this study, we analyzed Siglec15 expression within stromal area (SA) and tumor area (TA), and its relationship with tumor-infiltrating lymphocytes (TILs) in COAD and mismatch repair-proficient (MMR-p) COAD. Siglec15 expression was significantly higher in COAD tissues than in normal tissues, and elevated Siglec15(SA) expression, rather than Siglec15(TA) and Siglec15 (whole) expression, was correlated with poor prognosis and inversely correlated with the density of CD8⁺ T cell, both in COAD and MMR-p COAD. Moreover, there were no correlations between Siglec15(SA) and PD-L1(SA), and between Siglec15(TA) and PD-L1(TA), whereas there was positive correlation between Siglec15(whole) and PD-L1(whole). A new immune classification based on the Siglec15(SA)/PD-L1(SA) expression, indicated that patients with Siglec15(SA)^Low/PD-L1(SA)⁺ status had the longest survival times in COAD. Our study highlights that Siglec15(SA) is an independent predictor of poor prognosis and has an immunosuppressive role in COAD and MMR-p COAD tissues. These findings may provide insights into improving responses to immunotherapy-included comprehensive treatments for COAD in the future.

Keywords: Siglec15, PD-L1, immune checkpoint, immunotherapy, colon adenocarcinoma

Citation styles

APA

Zhan, W., Bai, F., Cai, Y., Zhang, J., Qin, G., Xie, Y., Deng, Y. (2023). Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma. Journal of Cancer, 14(16), 2998-3008. https://doi.org/10.7150/jca.87618.

ACS

Zhan, W.; Bai, F.; Cai, Y.; Zhang, J.; Qin, G.; Xie, Y.; Deng, Y. Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma. J. Cancer 2023, 14 (16), 2998-3008. DOI: 10.7150/jca.87618.

NLM

CSE

Zhan W, Bai F, Cai Y, Zhang J, Qin G, Xie Y, Deng Y. 2023. Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma. J Cancer. 14(16):2998-3008.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.